Outlook Therapeutics launches public stock offering By Investing.com

NodeGuardian · 2026-04-01T18:07:03+00:00

Outlook Therapeutics Inc. has launched a public offering of common stock and warrants to fund operations and address regulatory challenges in the U.S. for its ONS-5010 treatment, despite positive prospects in Europe.

NodeGuardian

2026-04-01 18:07:03

Abstract generation in progress

Outlook Therapeutics Inc. (NASDAQ:OTLK) has commenced a public offering of common stock and warrants, with H.C. Wainwright & Co. acting as the exclusive placement agent. The biopharmaceutical company, which develops bevacizumab treatments for retina diseases, plans to use the net proceeds for working capital and general corporate purposes. This comes as the company faces regulatory challenges in the U.S. for its ONS-5010/LYTENAVA treatment, despite receiving European marketing authorization and analyst predictions of significant sales growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes